Equillium to Present at Wells Fargo and H.C. Wainwright Healthcare Conferences

Equillium, Inc., a clinical-stage biotechnology company listed on Nasdaq under the ticker EQ, is set to participate in two significant upcoming investor conferences. The company, known for its expertise in immunobiology, focuses on developing innovative treatments for severe autoimmune and inflammatory diseases.

Equillium announced that it will present and engage with investors at the Wells Fargo Healthcare Conference and H.C. Wainwright’s 26th Annual Global Investor Conference. During these events, the company's management will provide insights into its multi-cytokine inhibitor programs and platform, particularly those targeting dermatological and gastrointestinal conditions. A key highlight of these discussions will be the ongoing development of itolizumab, a promising therapeutic agent, in collaboration with Ono Pharmaceutical. The decision by Ono regarding the potential acquisition of Equillium's rights to itolizumab is also anticipated to be a topic of interest.

The Wells Fargo Healthcare Conference will be held at Encore Boston Harbor from Wednesday, September 4 to Friday, September 6. Equillium is scheduled to present on Thursday, September 5, at 1:30 pm Pacific Time (4:30 pm Eastern Time). Meanwhile, the H.C. Wainwright 26th Annual Global Investor Conference will take place at the Lotte New York Palace Hotel from Monday, September 9 to Wednesday, September 11. Equillium’s presentation at this event is slated for Tuesday, September 10, at 5:00 am Pacific Time (8:00 am Eastern Time).

For those unable to attend in person, webcast access to both presentations will be available through the Events & Presentations page under the Investor Relations section on Equillium’s website. Additionally, an archived replay of the presentations will be accessible for 90 days.

Equillium is dedicated to harnessing its deep understanding of immunobiology to create novel therapeutics aimed at addressing unmet needs in autoimmune and inflammatory disorders. The company's pipeline includes several pioneering immunomodulatory assets and platforms that target immuno-inflammatory pathways. Notably, EQ101 is a selective tri-specific cytokine inhibitor that targets IL-2, IL-9, and IL-15, and has shown positive results in a Phase 2 proof-of-concept clinical study for alopecia areata. Another key asset, EQ302, is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21, currently in pre-clinical development.

The company’s multi-cytokine platform is designed to generate composite peptides that selectively inhibit key cytokines at the shared receptor level, effectively targeting pathogenic redundancies and synergies while preserving non-pathogenic signaling. Itolizumab, a monoclonal antibody targeting the CD6-ALCAM signaling pathway, is central to Equillium’s therapeutic strategy. This pathway plays a crucial role in modulating effector T cells. Itolizumab is currently being evaluated in a Phase 3 clinical study for acute graft-versus-host disease (aGVHD) and has reported positive data from a Phase 1b clinical study in patients with lupus/lupus nephritis in April 2024.

Equillium acquired the rights to itolizumab through an exclusive partnership with Biocon Limited and has entered into a strategic partnership with Ono Pharmaceutical Co., Ltd., for its development and commercialization. This collaboration includes an option and asset purchase agreement, underscoring the potential of itolizumab in treating severe autoimmune and inflammatory disorders.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!